Hengehold Capital Management LLC Acquires Shares of 4,241 Cencora, Inc. (NYSE:COR)

Hengehold Capital Management LLC acquired a new stake in Cencora, Inc. (NYSE:COR - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 4,241 shares of the company's stock, valued at approximately $952,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Financial Advocates Investment Management lifted its stake in Cencora by 4.7% in the second quarter. Financial Advocates Investment Management now owns 978 shares of the company's stock worth $220,000 after acquiring an additional 44 shares during the period. Checchi Capital Advisers LLC increased its holdings in Cencora by 2.2% during the second quarter. Checchi Capital Advisers LLC now owns 2,217 shares of the company's stock valued at $499,000 after buying an additional 48 shares during the period. Valeo Financial Advisors LLC raised its stake in Cencora by 3.4% in the second quarter. Valeo Financial Advisors LLC now owns 1,566 shares of the company's stock worth $353,000 after buying an additional 51 shares in the last quarter. Evergreen Capital Management LLC lifted its holdings in Cencora by 4.7% during the second quarter. Evergreen Capital Management LLC now owns 1,147 shares of the company's stock worth $258,000 after buying an additional 52 shares during the period. Finally, Vontobel Holding Ltd. boosted its position in Cencora by 1.4% during the 3rd quarter. Vontobel Holding Ltd. now owns 4,250 shares of the company's stock valued at $957,000 after acquiring an additional 58 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.

Cencora Stock Performance

Shares of COR traded down $0.93 during trading hours on Thursday, reaching $235.64. 1,231,775 shares of the company traded hands, compared to its average volume of 1,424,812. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. The business has a fifty day moving average price of $232.42 and a 200-day moving average price of $231.15. Cencora, Inc. has a 12-month low of $182.75 and a 12-month high of $247.66. The stock has a market capitalization of $47.00 billion, a P/E ratio of 25.89, a P/E/G ratio of 1.40 and a beta of 0.44.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, beating the consensus estimate of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The business had revenue of $74.20 billion for the quarter, compared to the consensus estimate of $73.32 billion. During the same quarter in the previous year, the business earned $2.92 EPS. The company's quarterly revenue was up 10.8% compared to the same quarter last year. Equities analysts anticipate that Cencora, Inc. will post 13.63 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were issued a $0.51 dividend. This represents a $2.04 annualized dividend and a dividend yield of 0.87%. The ex-dividend date was Friday, August 9th. Cencora's dividend payout ratio (DPR) is currently 22.32%.

Insider Transactions at Cencora

In related news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the business's stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the completion of the transaction, the insider now directly owns 19,980,000 shares in the company, valued at $4,806,388,800. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of Cencora stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the completion of the transaction, the insider now directly owns 19,980,000 shares in the company, valued at approximately $4,806,388,800. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,473 shares of the company's stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the sale, the executive vice president now owns 10,948 shares in the company, valued at approximately $2,656,970.12. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 15.80% of the company's stock.

Analyst Ratings Changes

COR has been the subject of a number of analyst reports. Bank of America restated a "neutral" rating and set a $245.00 price objective (down from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Wells Fargo & Company raised their price target on shares of Cencora from $236.00 to $249.00 and gave the company an "equal weight" rating in a report on Thursday, August 1st. JPMorgan Chase & Co. boosted their price objective on shares of Cencora from $280.00 to $287.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 21st. Robert W. Baird lowered their target price on shares of Cencora from $287.00 to $283.00 and set an "outperform" rating for the company in a research note on Friday, September 6th. Finally, StockNews.com lowered shares of Cencora from a "strong-buy" rating to a "buy" rating in a report on Friday, September 20th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $259.44.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.